Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventric...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko
Format:	Artikel
Sprache:	Russian
Veröffentlicht:	"Consilium Medicum" Publishing house 2015-09-01
Schriftenreihe:	Терапевтический архив
Schlagworte:	aldosterone mineralocorticoid receptor antagonists chronic heart failure
Online Zugang:	https://ter-arkhiv.ru/0040-3660/article/view/31823

Ähnliche Einträge

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
von: S N Tereshchenko, et al.
Veröffentlicht: (2013-12-01)

Heart failure: the role for mineralocorticoid receptor antagonists
von: Bertram Pitt
Veröffentlicht: (2014-05-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
von: Natalia V. Safronova, et al.
Veröffentlicht: (2022-01-01)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
von: Jason M. Duran, et al.
Veröffentlicht: (2020-04-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
von: A. M. Esayan, et al.
Veröffentlicht: (2018-04-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
von: Josefin Henrysson, et al.
Veröffentlicht: (2023-02-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
von: Daiji Kawanami, et al.
Veröffentlicht: (2021-10-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
von: MG Bubnova
Veröffentlicht: (2014-12-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
von: Yuta Tezuka, et al.
Veröffentlicht: (2021-03-01)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
von: Mary Elizabeth Moss, et al.
Veröffentlicht: (2015-09-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
von: Pascal R. D. Clephas, et al.
Veröffentlicht: (2023-04-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
von: Takuro Abe, et al.
Veröffentlicht: (2020-10-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
von: Arga Setyo Adji, et al.
Veröffentlicht: (2024-11-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
von: Irina N. Bobkova
Veröffentlicht: (2023-11-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
von: Shuhui Zhai, et al.
Veröffentlicht: (2024-09-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
von: Memory MUKANGWA, et al.
Veröffentlicht: (2019-12-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
von: O. A. Osipova, et al.
Veröffentlicht: (2021-11-01)

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
von: Ida Löfman, et al.
Veröffentlicht: (2018-07-01)

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
von: Eqerem Hasani, et al.
Veröffentlicht: (2022-01-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
von: Sho Suzuki, et al.
Veröffentlicht: (2020-10-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
von: N. A. Nuritdinov, et al.
Veröffentlicht: (2020-12-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
von: Houry Puzantian, et al.
Veröffentlicht: (2024-12-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
von: Chang Geng, et al.
Veröffentlicht: (2023-11-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
von: Kisho Miyasako, et al.
Veröffentlicht: (2024-12-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
von: Luo Shi, et al.
Veröffentlicht: (2019-11-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
von: Ulrich Kintscher, et al.
Veröffentlicht: (2023-06-01)

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
von: Nappi J, et al.
Veröffentlicht: (2011-06-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
von: Chien‐Wei Huang, et al.
Veröffentlicht: (2025-02-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
von: A. G. Evdokimova, et al.
Veröffentlicht: (2023-01-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
von: Andrei Niculae, et al.
Veröffentlicht: (2022-03-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
von: Nina Vodošek Hojs, et al.
Veröffentlicht: (2021-06-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
von: Irene Lucía Ennis, et al.
Veröffentlicht: (2021-01-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
von: Greg H. Tesch, et al.
Veröffentlicht: (2017-05-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
von: S. R. Gilyarevsky, et al.
Veröffentlicht: (2023-10-01)

Heart failure as a complication of myocardial infarction: rational therapy. Case report
von: Igor V. Zhirov, et al.
Veröffentlicht: (2022-12-01)

New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
von: Natalia A. Dragomiretskaya, et al.
Veröffentlicht: (2021-09-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
von: Dong-Lim Kim, et al.
Veröffentlicht: (2023-02-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
von: Stephen eOrena, et al.
Veröffentlicht: (2013-10-01)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
von: Marie Pieronne‐Deperrois, et al.
Veröffentlicht: (2021-06-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
von: Sofia S. Pereira, et al.
Veröffentlicht: (2021-04-01)